Keyphrases
Randomized Placebo-controlled Trial
100%
Agonist Treatment
100%
GLP-1 Receptor Agonist
100%
Patients with Schizophrenia
100%
Antipsychotics
100%
Exenatide
50%
Glucagon-like
33%
Schizophrenia
33%
Receptor Agonist
33%
A1 Receptor
33%
Weight Loss
33%
Obesity
33%
Placebo
33%
Placebo Groups
33%
Non-diabetic
33%
Exenatide Once Weekly
33%
Receptor System
16%
Glucagon-like peptide-1 Receptor (GLP-1R)
16%
Diabetes
16%
Type 2 Diabetes Mellitus (T2DM)
16%
Life Expectancy
16%
Anti-obesity
16%
Group Differences
16%
Adjunctive Therapy
16%
Treatment Standards
16%
Patient-completed
16%
Repeated Measures Analysis of Variance
16%
Obese Patients
16%
March 2013
16%
Weight Reduction
16%
Statistical Analysis
16%
Schizophrenia Spectrum Disorders
16%
Once-weekly
16%
Cardiovascular Comorbidities
16%
Metabolic Effects
16%
Dopaminergic Signaling
16%
Medicine and Dentistry
Antipsychotic
100%
Exenatide
100%
Glucagon-Like Peptide-1 Agonist
100%
Placebo
100%
Body Weight
100%
Diabetes Mellitus
40%
Maturity Onset Diabetes of the Young
20%
Receptor
20%
Population
20%
Analysis of Variance
20%
Cardiovascular System
20%
Side Effect
20%
Medical Care
20%
Comorbidity
20%
Diabetes
20%
Life Expectancy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Antipsychotic
100%
Placebo
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Exendin 4
100%
Diabetes Mellitus
40%
Side Effect
20%
Life Expectancy
20%
Receptor
20%
Dopamine 2 Receptor Blocking Agent
20%
Non Insulin Dependent Diabetes Mellitus
20%
Dopamine Receptor Stimulating Agent
20%
Comorbidity
20%
Neuroscience
Placebo
100%
Glucagon-Like Peptide-1 Agonist
100%
Antipsychotic
100%
Exenatide
100%
Diabetes Mellitus
40%
Dopamine Receptor D2
20%
Receptor
20%
Comorbidity
20%
Dopaminergic
20%
Receptor Antagonist
20%